The focus of this podcast episode is the critical importance of evaluating Electronic Quality Management Systems (EQMS) platforms at the appropriate stages of product development rather than waiting for a crisis to prompt action. I explore how proactive medtech teams that prioritize early evaluation of EQMS platforms position themselves for success, ultimately enhancing their capacity to bring safer and more effective medical devices to market. Joined by industry expert Andy Rogantino, we delve into the intricacies of when and how teams should consider EQMS solutions, emphasizing the necessity for a foundational quality system that supports regulatory compliance and operational efficiency. Our discussion also highlights the essential collaboration among product development, quality assurance, and leadership to ensure that the chosen EQMS aligns with the unique needs of each organization. By understanding these dynamics, we aim to equip medtech professionals with the knowledge to make informed decisions that will positively impact patient outcomes and organizational success.

na

Takeaways:

• The most effective medtech companies evaluate EQMS platforms early in their development process to avoid regulatory headaches later on.
• Quality management systems should be viewed as the backbone of medical device development, essential for improving patient outcomes and compliance.
• Companies need to adopt a proactive mindset in quality management, as waiting for issues to arise can lead to dire consequences.
• A successful EQMS implementation requires collaboration across various departments including regulatory, quality, and product development.
• It is crucial for medical device teams to consider the user experience of the EQMS software, ensuring it is intuitive and effective for everyday use.
• Evaluating the ROI of an EQMS should encompass not only financial metrics but also improvements in efficiency and compliance readiness.

Links referenced in this episode:

• www.greenlight.guru
• podcastreenlight.guru

Companies mentioned in this episode:

• AbbVie
• Signal Therapeutics
• Second Nature
• Greenlight Guru